Affibody AB

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration

Gossamer Bio, Inc. is testing its inhaled kinase inhibitor seralutinib in a Phase III clinical trial as a potential disease-modifying treatment for pulmonary arterial hypertension (PAH), but has its

There are a number of contenders hoping to get into the hidradenitis suppurativa (HS) market soon but they will have to play catch with Novartis AG 's Cosentyx which has just received a green light i